Large cell carcinoma

Summary

Large cell carcinoma (MONDO:0005232) is a cancer (an umbrella term covering 5 Mondo subtypes) and 9 clinical trials. Top therapeutic interventions include carboplatin, crizotinib, and dacomitinib anhydrous. A subtype of carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	large cell carcinoma
Mondo ID	MONDO:0005232
MeSH	D018287
DOID	DOID:4552
NCIT	C3780
UMLS	C0206704
MedGen	61665
Is cancer (heuristic)	yes

Also known as: carcinoma, large cell · large cell carcinoma

Disease family

This is a subtype of carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › large cell carcinoma

Related subtypes (48): retroperitoneum carcinoma, head and neck carcinoma, peritoneal carcinoma, neuroendocrine carcinoma, laryngeal carcinoma, bone carcinoma, carcinoma ex pleomorphic adenoma, scrotal carcinoma, skin carcinoma, malignant myoepithelioma, trachea carcinoma, epithelial-myoepithelial carcinoma, lipid-rich carcinoma, comedocarcinoma, in situ carcinoma, adenocarcinoma, urinary bladder carcinoma, breast carcinoma, squamous cell carcinoma, lung carcinoma, prostate carcinoma, renal carcinoma, uterine carcinoma, vulvar carcinoma, undifferentiated carcinoma, basaloid carcinoma, cribriform carcinoma, digestive system carcinoma, fallopian tube carcinoma, penile carcinoma, sarcomatoid carcinoma, thymic carcinoma, transitional cell carcinoma, ureter carcinoma, papillary carcinoma, Krebs 2 carcinoma, thyroid gland carcinoma, vaginal carcinoma, choroid plexus carcinoma, malignant epithelial tumor of ovary, mucin-producing carcinoma, basal cell carcinoma, carcinoma of urethra, combined carcinoid and adenocarcinoma, secondary carcinoma, invasive carcinoma, glycogen-rich carcinoma, lymph node carcinoma

Subtypes (5): lung large cell carcinoma, nasopharyngeal type undifferentiated carcinoma, large cell neuroendocrine carcinoma, salivary gland large cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	2
PHASE3	2
PHASE2	2
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01317615	PHASE4	COMPLETED	RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
NCT02151149	PHASE4	COMPLETED	Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT00596830	PHASE3	TERMINATED	Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
NCT00673049	PHASE3	TERMINATED	Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
NCT00073398	PHASE1/PHASE2	COMPLETED	Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NCT00632203	PHASE2	TERMINATED	Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
NCT01497041	PHASE2	UNKNOWN	A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
NCT01441128	PHASE1	TERMINATED	-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
NCT05337163	Not specified	COMPLETED	A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	3
CRIZOTINIB	4	1
DACOMITINIB ANHYDROUS	4	1
ERLOTINIB	4	1
EVEROLIMUS	4	1
PACLITAXEL	4	1
FIGITUMUMAB	3	1
CHEMBL48	0	1